Biology of Bladder Cancer

Maggie Knowles, PhD is Emeritus Professor of Experimental Cancer Research at the University of Leeds in the UK. She has worked on bladder cancer for more than forty years with the goal of improving disease management through molecular studies.  Her work has included identification of key genes involved in the development of bladder cancer, sub-classification of non-invasive tumours through genomic and transcriptional analyses and development of in vitro models for preclinical validation of potential therapeutic targets and improved understanding of gene function.  Her extensive publications and leadership roles have played an important part in shaping bladder cancer research over the past two decades.

Lars Dyrskjøt, PhD, is a Professor of Molecular Medicine at Aarhus University in Denmark, where he leads a team focused on translational bladder cancer research. His work has greatly enhanced understanding of the disease's molecular pathogenesis, especially through the identification of prognostic and predictive biomarkers in early-stage bladder cancer, and the innovative use of liquid biopsies for monitoring and guiding treatment in advanced bladder cancer. With his extensive publications and leadership roles in international cancer research initiatives, Prof. Dyrskjøt plays a crucial role in advancing the global discourse on bladder cancer.

Part I. Fundamentals of Bladder Cancer.- Chapter 1. Epidemiology of Bladder Cancer.- Chapter 2. Genetic Predisposition to Bladder Cancer.- Chapter 3. Human Urothelium.- Chapter 4. Bladder Cancer Pathology.- Chapter 5. Overview of Standard Therapy of Non Muscle-Invasive Bladder Cancer.- Chapter 6. Overview of Standard Therapy of Muscle-Invasive Bladder Cancer.- Part II. Molecular Genetics and Oncogenesis in Bladder Cancer.- Chapter 7. From Normalcy to Neoplasia: Mutational Events during Bladder Tumor Evolution.- Chapter 8. Cell Cycle Regulators as Oncogenic Drivers in Bladder Cancer.- Chapter 9. DNA Repair Pathway Alterations in Bladder Cancer.- Chapter 10. DNA Methylation and Chromatin Regulators in Bladder Cancer.- Part III. Pathogenesis and Microenvironment Dynamics in Bladder Cancer.- Chapter 11. Molecular Pathogenesis: Field Cancerization and Clonal Evolution in Urothelial Cancer Initiation and Progression.- Chapter 12. The Bladder Tumor Microenvironment.- Part IV. Molecular and Histological Subtypes of Bladder Cancer.- Chapter 13. Molecular Subtypes of Non-Muscle-Invasive Bladder Cancer.- Chapter 14. Molecular Subtypes of Muscle-Invasive Bladder Cancer.- Chapter 15. Molecular Features of Divergent Differentiation and Histological Subtypes in Bladder Cancer.- Part V. Experimental Models of Bladder Cancer.- Chapter 16. The Emerging Landscape of Mouse Bladder Cancer Models.- Chapter 17. In Vitro Bladder Cancer Models.- Part VI. Biomarkers for Diagnosis and Treatment of Bladder Cancer.- Chapter 18. Urine Biomarkers for Bladder Cancer Diagnosis and Screening.- Chapter 19. Blood-Based Biomarkers for Bladder Cancer Diagnosis and Prognosis.- Chapter 20. Mechanisms and Biomarkers of Response to BCG and Chemotherapy in Bladder Cancer.- Part VII. Therapeutic Application based on Molecular Insights.- Chapter 21. New Treatment Approaches in Non-Muscle-Invasive Bladder Cancer.- Chapter 22. New Treatment Approaches in Muscle-Invasive Bladder Cancer.- Chapter 23. Targeting the Immune Checkpoint in Bladder Cancer.- Part VIII. Future Directions in Bladder Cancer Research.- Chapter 24. Future Directions in Bladder Cancer Research and Clinical Implications.